$BIMI
BIMI Holdings Inc. Stock $bimi

$bimi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000121390023036407 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022
Revenue	$5.558M	$11.83M	$11.83M
YoY Change	12.79%	530.18%	-56.31%
Cost Of Revenue	$2.674M	$9.880M	$9.880M
YoY Change	-27.78%	429.18%	-56.05%
Gross Profit	$2.884M	$1.950M	$1.950M
YoY Change	135.35%	19054.72%	-57.58%
Gross Profit Margin	51.89%	16.48%	16.48%
Selling, General & Admin	$1.585M	$11.90M	$11.90M
YoY Change	-54.78%	274.18%	-6.3%
% of Gross Profit	54.94%	610.4%	610.41%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$80.00K	$58.32K	$77.94K
YoY Change	118.46%	-10.24%	-68.07%
% of Gross Profit	2.77%	2.99%	4.0%
Operating Expenses	$1.585M	$11.90M	$17.29M
YoY Change	-54.78%	274.18%	36.09%
Operating Profit	$1.299M	-$9.953M	-$15.34M
YoY Change	-157.02%	213.89%	89.2%
Interest Expense	$34.62K	-$176.4K	$170.5K
YoY Change	-68.97%	75.57%	-152.78%
% of Operating Profit	2.66%
Other Income/Expense, Net	-$125.1K	-$6.108M	-$6.284M
YoY Change	-93.27%	2207.68%	1725.38%
Pretax Income	$1.174M	-$21.62M	-$21.62M
YoY Change	-128.38%	-27.11%	-38.05%
Income Tax		$6.090K	$6.092K
% Of Pretax Income
Net Earnings	$1.054M	-$22.39M	-$22.39M
YoY Change	-125.43%	-24.53%	-35.99%
Net Earnings / Revenue	18.97%	-189.29%	-189.29%
Basic Earnings Per Share	$0.23		-$8.38
Diluted Earnings Per Share	$0.23	-$8.40	-$8.38
COMMON SHARES
Basic Shares Outstanding	4.385M shares	38.43M shares	2.665M shares
Diluted Shares Outstanding	4.596M shares		2.665M shares

Balance Sheet

Concept	2023 Q2	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.930M	$2.337M	$2.337M
YoY Change	-61.66%	-51.3%	-51.3%
Cash & Equivalents	$1.932M	$2.337M	$2.337M
Short-Term Investments
Other Short-Term Assets	$10.48M	$9.137M	$9.137M
YoY Change	41.78%	92.41%	92.41%
Inventory	$7.183M	$7.654M	$7.654M
Prepaid Expenses
Receivables	$6.380M	$3.208M	$3.208M
Other Receivables	$30.00K	$899.9K	$899.9K
Total Short-Term Assets	$26.00M	$23.24M	$23.24M
YoY Change	7.52%	9.81%	9.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.690M	$1.703M	$4.646M
YoY Change	-45.7%	-51.63%	-44.48%
Goodwill	$2.066M	$2.066M
YoY Change	-75.34%	-75.34%
Intangibles	$448.9K	$16.18K
YoY Change	2573.32%	-10.29%
Long-Term Investments		$1.800M	$1.800M
YoY Change
Other Assets	$3.620M	$3.951M	$3.951M
YoY Change	1735.98%	1803.77%	1803.77%
Total Long-Term Assets	$10.66M	$12.48M	$12.48M
YoY Change	-33.52%	-26.46%	-26.46%
TOTAL ASSETS
Total Short-Term Assets	$26.00M	$23.24M	$23.24M
Total Long-Term Assets	$10.66M	$12.48M	$12.48M
Total Assets	$36.66M	$35.71M	$35.71M
YoY Change	-8.85%	-6.33%	-6.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.610M	$10.79M	$10.79M
YoY Change	64.29%	46.96%	46.96%
Accrued Expenses	$3.270M	$3.078M	$3.078M
YoY Change	6.01%	-0.16%	-0.16%
Deferred Revenue
YoY Change
Short-Term Debt	$1.135M	$818.4K	$1.927M
YoY Change	-31.5%	-54.52%	-72.51%
Long-Term Debt Due	$101.2K	$106.0K	$106.0K
YoY Change	-72.58%	-71.3%	-71.3%
Total Short-Term Liabilities	$19.39M	$25.36M	$25.36M
YoY Change	-9.85%	14.8%	14.8%
LONG-TERM LIABILITIES
Long-Term Debt	$126.3K	$314.8K	$314.8K
YoY Change	-73.22%	-41.49%	-41.49%
Other Long-Term Liabilities	$4.630M	$4.820M	$4.820M
YoY Change	20.57%	15.82%	15.82%
Total Long-Term Liabilities	$4.755M	$314.8K	$5.135M
YoY Change	10.29%	-93.3%	9.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.39M	$25.36M	$25.36M
Total Long-Term Liabilities	$4.755M	$314.8K	$5.135M
Total Liabilities	$24.15M	$30.50M	$31.67M
YoY Change	-6.49%	13.83%	17.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.30M	-$70.14M
YoY Change		46.44%
Common Stock	$6.259K	$3.765K
YoY Change	-99.99%	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.89M	$4.048M	$4.048M
YoY Change
Total Liabilities & Shareholders Equity	$36.66M	$35.71M	$35.71M
YoY Change	-8.85%	-6.33%	-6.33%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$1.054M	-$22.39M	-$22.39M
YoY Change	-125.43%	-24.53%	-35.99%
Depreciation, Depletion And Amortization	$80.00K	$58.32K	$77.94K
YoY Change	118.46%	-10.24%	-68.07%
Cash From Operating Activities	-$570.0K	-$2.925M	-$10.26M
YoY Change	-118.35%	-329.93%	703.87%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions		$2.768M	$1.800M
YoY Change
Other Investing Activities		-$356.9K	-$536.9K
YoY Change		-402.0%	-554.32%
Cash From Investing Activities		-$356.9K	-$536.9K
YoY Change		-132.21%	-22.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	330.0K	4.075M	$8.434M
YoY Change	33.51%	150.7%	37.34%
NET CHANGE
Cash From Operating Activities	-570.0K	-2.925M	-$10.26M
Cash From Investing Activities		-356.9K	-$536.9K
Cash From Financing Activities	330.0K	4.075M	$8.434M
Net Change In Cash	-240.0K	793.4K	-$2.273M
YoY Change	-107.16%	-80.2%	-154.53%
FREE CASH FLOW
Cash From Operating Activities	-$570.0K	-$2.925M	-$10.26M
Capital Expenditures
Free Cash Flow			-$10.26M
YoY Change			2124.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.26
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.43
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-65.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.38
CY2022	bimi	Disposal Of Discontinued Operations And Subsidiariesdisposal DisposalOfDiscontinuedOperationsAndSubsidiariesdisposal		usd
CY2021	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary		usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
CY2021	bimi	Disposal Of Zhuoda DisposalOfZhuoda		usd
CY2022	bimi	Payment For The Acquisition Of Qiangsheng Eurasia And Mingkang Hospitals PaymentForTheAcquisitionOfQiangshengEurasiaAndMingkangHospitals		usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	bimi	Deposit For The Acquisition Of Cogmer DepositForTheAcquisitionOfCogmer		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2021	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit		usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022	bimi	Outstanding Payment For Equity Acquisition Of Guanzan Group OutstandingPaymentForEquityAcquisitionOfGuanzanGroup		usd
CY2022	bimi	Issuance Of Common Share For Equity IssuanceOfCommonShareForEquity		usd
CY2021	bimi	Issuance Of Common Share For Equity IssuanceOfCommonShareForEquity		usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2022	bimi	Issuance Of Common Share For Equity Acquisition Of Minkang Hospital IssuanceOfCommonShareForEquityAcquisitionOfMinkangHospital		usd
CY2021	bimi	Issuance Of Common Share For Equity Acquisition Of Minkang Hospital IssuanceOfCommonShareForEquityAcquisitionOfMinkangHospital		usd
CY2022	bimi	Issuance Of Shares Of Common Stock For Prepayment Of Equity Acquisition Of Zhuoda IssuanceOfSharesOfCommonStockForPrepaymentOfEquityAcquisitionOfZhuoda		usd
CY2021	bimi	Issuance Of Shares Of Common Stock For Prepayment Of Equity Acquisition Of Zhuoda IssuanceOfSharesOfCommonStockForPrepaymentOfEquityAcquisitionOfZhuoda		usd
CY2022	bimi	Issuance Of Shares Of Common Stock For Payment Of Improvements To Offices IssuanceOfSharesOfCommonStockForPaymentOfImprovementsToOffices		usd
CY2022	bimi	Goodwill Recognized From Equity Acquisition Of Zhongshan Chaohu Hospital GoodwillRecognizedFromEquityAcquisitionOfZhongshanChaohuHospital		usd
CY2021	bimi	Goodwill Recognized From Equity Acquisition Of Zhongshan Chaohu Hospital GoodwillRecognizedFromEquityAcquisitionOfZhongshanChaohuHospital		usd
CY2022	bimi	Goodwill Recognized From Equity Acquisition Of Guanzan Group GoodwillRecognizedFromEquityAcquisitionOfGuanzanGroup		usd
CY2022	bimi	Goodwill Recognized From Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospital GoodwillRecognizedFromEquityAcquisitionOfMinkangQiangshengAndEurasiaHospital		usd
CY2021	bimi	Goodwill Recognized From Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospital GoodwillRecognizedFromEquityAcquisitionOfMinkangQiangshengAndEurasiaHospital		usd
CY2022	bimi	Outstanding Payment For Equity Acquisition Of Zhuoda OutstandingPaymentForEquityAcquisitionOfZhuoda		usd
CY2021	bimi	Outstanding Payment For Equity Acquisition Of Zhuoda OutstandingPaymentForEquityAcquisitionOfZhuoda		usd
CY2022	bimi	Outstanding Payment For Equity Acquisition OutstandingPaymentForEquityAcquisition		usd
CY2022	bimi	Outstanding Payment For Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospitals OutstandingPaymentForEquityAcquisitionOfMinkangQiangshengAndEurasiaHospitals		usd
CY2021	bimi	Outstanding Payment For Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospitals OutstandingPaymentForEquityAcquisitionOfMinkangQiangshengAndEurasiaHospitals		usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability		usd
CY2021Q4	us-gaap	Security Deposit Liability SecurityDepositLiability		usd
CY2021	us-gaap	Increase Decrease In Earnest Money Deposits Outstanding IncreaseDecreaseInEarnestMoneyDepositsOutstanding		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-50155
CY2022	dei	Entity Registrant Name EntityRegistrantName	BIMI International Medical Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	02-0563302
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	725 5th Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	15th Floor
CY2022	dei	Entity Address Address Line3 EntityAddressAddressLine3	15-01
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	400010
CY2022	dei	City Area Code CityAreaCode	212
CY2022	dei	Local Phone Number LocalPhoneNumber	542 0028
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable		usd
CY2022Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet		usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities		usd
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments		usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1966809	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments		usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation		usd
CY2022	bimi	Addition During The Year AdditionDuringTheYear		usd
CY2022	dei	Trading Symbol TradingSymbol	BIMI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4384780	shares
CY2022	dei	Auditor Firm AuditorFirmId	3487
CY2022	dei	Auditor Name AuditorName	Audit Alliance LLP
CY2022	dei	Auditor Location AuditorLocation	Singapore
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2336636	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4609431	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3208286	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5874607	usd
CY2022Q4	us-gaap	Supplies Supplies	6589759	usd
CY2021Q4	us-gaap	Supplies Supplies	2909048	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7654242	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2238692	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1347079	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1811182	usd
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	2091836	usd
CY2022Q4	bimi	Current Assets From Discontinued Operationsheld For Sale CurrentAssetsFromDiscontinuedOperationsheldForSale	2099673	usd
CY2021Q4	bimi	Current Assets From Discontinued Operationsheld For Sale CurrentAssetsFromDiscontinuedOperationsheldForSale	1624854	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	23235675	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21159650	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	190132	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	207694	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1703420	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1945552	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16183	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18039	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2942265	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1708740	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2065666	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8376217	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1800000	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	18466	usd
CY2022Q4	bimi	Noncurrent Assets From Discontinued Operationsheld For Sale NoncurrentAssetsFromDiscontinuedOperationsheldForSale	3761149	usd
CY2021Q4	bimi	Noncurrent Assets From Discontinued Operationsheld For Sale NoncurrentAssetsFromDiscontinuedOperationsheldForSale	4694007	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12478815	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16968715	usd
CY2022Q4	us-gaap	Assets Assets	35714490	usd
CY2021Q4	us-gaap	Assets Assets	38128365	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	818425	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	768543	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	105965	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	369187	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1108785	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5211160	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10785531	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5202818	usd
CY2022Q4	bimi	Advances From Customers AdvancesFromCustomers	923131	usd
CY2021Q4	bimi	Advances From Customers AdvancesFromCustomers	1893819	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4600441	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	730285	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	71915	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	308503	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3175574	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2080285	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	532630	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	442628	usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1539327	usd
CY2022Q4	bimi	Current Liabilities From Discontinued Operationsheld For Sale CurrentLiabilitiesFromDiscontinuedOperationsheldForSale	3239950	usd
CY2021Q4	bimi	Current Liabilities From Discontinued Operationsheld For Sale CurrentLiabilitiesFromDiscontinuedOperationsheldForSale	3545587	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25362347	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22092142	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2574751	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1402550	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	314786	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	538006	usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	12727	usd
CY2022Q4	bimi	Noncurrent Liabilities From Discontined Operationsheld For Sale NoncurrentLiabilitiesFromDiscontinedOperationsheldForSale	2245373	usd
CY2021Q4	bimi	Noncurrent Liabilities From Discontined Operationsheld For Sale NoncurrentLiabilitiesFromDiscontinedOperationsheldForSale	2746512	usd
CY2022Q4	us-gaap	Liabilities Liabilities	30497257	usd
CY2021Q4	us-gaap	Liabilities Liabilities	26791937	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3764780	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3764780	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	850222	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	850222	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	71899271	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55227782	usd
CY2022Q4	bimi	Statutory Reserves StatutoryReserves	2263857	usd
CY2021Q4	bimi	Statutory Reserves StatutoryReserves	2263857	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70143785	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47900930	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24583	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1601872	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4047691	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11193431	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1169542	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	142997	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5217233	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11336428	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35714490	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38128365	usd
CY2022	us-gaap	Revenues Revenues	11830379	usd
CY2021	us-gaap	Revenues Revenues	21319610	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	9880429	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	18893667	usd
CY2022	us-gaap	Gross Profit GrossProfit	1949950	usd
CY2021	us-gaap	Gross Profit GrossProfit	2425943	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1302775	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2153205	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10599818	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6056584	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5385811	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	26128171	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	17288404	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	34337960	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15338454	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-31912017	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	707	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	3087	usd
CY2022	us-gaap	Interest Expense InterestExpense	170480	usd
CY2021	us-gaap	Interest Expense InterestExpense	190829	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6583	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	24967	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-3260788	usd
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2252401	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2846716	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-336752	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6283860	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2751928	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21622314	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34663945	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6092	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29674	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-21628406	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-34693619	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-40505	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	714	usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-649145	usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-228840	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-22318056	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-34921745	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	75203	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	64211	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-22393259	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-34985956	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1577289	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	598481	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-23895345	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-34323264	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1052601	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-26056	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22842744	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34297208	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2664653	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	536293	shares
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-8.12
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-64.69
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.26
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.43
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-65.12
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16893471	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26460683	usd
CY2021	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-32544181	usd
CY2021	bimi	Disposal Of Discontinued Operations And Subsidiariesdisposal DisposalOfDiscontinuedOperationsAndSubsidiariesdisposal	558248	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-616305	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	584512	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11336428	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16674404	usd
CY2022	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-23445860	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-3221789	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	3874050	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5217233	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-22318056	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-34921745	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	223561	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	244116	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	5385811	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	26128171	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	59567	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	93884	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1380929	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-53698	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3260788	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2252401	usd
CY2022	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	529320	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1357394	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-877440	usd
CY2022	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	-490168	usd
CY2021	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	203053	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5475117	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1429785	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-464103	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-4915327	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1233525	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1214165	usd
CY2022	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	5582713	usd
CY2021	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	-1248623	usd
CY2022	bimi	Increase Decrease I Advances From Customers IncreaseDecreaseIAdvancesFromCustomers	-970688	usd
CY2021	bimi	Increase Decrease I Advances From Customers IncreaseDecreaseIAdvancesFromCustomers	1699733	usd
CY2022	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	1262203	usd
CY2021	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	1283039	usd
CY2022	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-219026	usd
CY2021	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-479750	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1095289	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2380066	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10255206	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4436774	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10255206	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4436774	usd
CY2021	bimi	Cash Received From Acquisition Of Subsidiaries CashReceivedFromAcquisitionOfSubsidiaries	28457	usd
CY2022	bimi	Disposal Of Zhuoda DisposalOfZhuoda	924740	usd
CY2021	bimi	Payment For The Acquisition Of Qiangsheng Eurasia And Mingkang Hospitals PaymentForTheAcquisitionOfQiangshengEurasiaAndMingkangHospitals	3136910	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1800000	usd
CY2021	bimi	Deposit For The Acquisition Of Cogmer DepositForTheAcquisitionOfCogmer	-3065181	usd
CY2022	bimi	Discontinued Operations Disposal Of Zhuoda DiscontinuedOperationsDisposalOfZhuoda	-27117	usd
CY2021	bimi	Discontinued Operations Disposal Of Zhuoda DiscontinuedOperationsDisposalOfZhuoda	886910	usd
CY2022	bimi	Discontinue Operationsheld For Sale Of Zhongshan Qiangsheng Eurasia And Mingkang DiscontinueOperationsheldForSaleOfZhongshanQiangshengEurasiaAndMingkang	311277	usd
CY2021	bimi	Discontinue Operationsheld For Sale Of Zhongshan Qiangsheng Eurasia And Mingkang DiscontinueOperationsheldForSaleOfZhongshanQiangshengEurasiaAndMingkang	2483549	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	242726	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-536866	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1310641	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-536866	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1310641	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	usd
CY2021	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	-135685	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	151995	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6500000	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	49882	usd
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	486442	usd
CY2022	bimi	Amount Financed From Related Parties AmountFinancedFromRelatedParties	3870156	usd
CY2021	bimi	Amount Financed From Related Parties AmountFinancedFromRelatedParties	361573	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8433596	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6877883	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8433596	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6877883	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85681	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	722372	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2272795	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4474122	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4609431	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135309	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2336636	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4609431	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	6092	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	422033	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	163326	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	163883	usd
CY2021	bimi	Outstanding Payment For Equity Acquisition Of Guanzan Group OutstandingPaymentForEquityAcquisitionOfGuanzanGroup	3818000	usd
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3820000	usd
CY2021	bimi	Issuance Of Shares Of Common Stock For Payment Of Improvements To Offices IssuanceOfSharesOfCommonStockForPaymentOfImprovementsToOffices	696896	usd
CY2021	bimi	Goodwill Recognized From Equity Acquisition Of Guanzan Group GoodwillRecognizedFromEquityAcquisitionOfGuanzanGroup	7154392	usd
CY2021	bimi	Outstanding Payment For Equity Acquisition OutstandingPaymentForEquityAcquisition	6100723	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5400000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. ORGANIZATION AND BUSINESS BACKGROUND</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">BIMI International Medical, Inc. (the “Company” or “BIMI”) was incorporated in the State of Delaware as Galli Process, Inc. on October 31, 2000. On February 7, 2002, the Company changed its name to Global Broadcast Group, Inc. On November 12, 2004, the Company changed its name to Diagnostic Corporation of America. On March 15, 2007, the Company changed its name to NF Energy Saving Corporation of America, and on August 24, 2009, the Company changed its name to NF Energy Saving Corporation. On December 16, 2019, the Company changed its name to BOQI International Medical Inc., to reflect the Company’s refocus of its business from the energy saving industry to the health care industry. Since March 7, 2012, the common stock of the Company (the “Common Stock”) has been traded on the Nasdaq Capital Market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Until October 14, 2019, the Company, through NF Energy Saving Investment Limited and its subsidiaries (the “NF Group”), operated in the energy saving enhancement technology industry in the People’s Republic of China (the “PRC”). The NF Group focused on providing services relating to energy saving technology, optimization design, energy saving reconstruction of pipeline networks and contractual energy management for the electric power, petrochemical, coal, metallurgy, construction, and municipal infrastructure development industries in the PRC and the manufacture and sales of energy-saving flow control equipment. In late 2019, the Company committed to a plan to dispose of all its equity interests in the NF Group and on March 31, 2020, the Company entered into an agreement to sell the NF Group. The sale of the NF Group closed on June 23, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On October 14, 2019, the Company acquired 100% of the equity interests in Lasting Wisdom Holdings Limited (“Lasting”), a limited company incorporated under the laws of the British Virgin Islands (“BVI”). Lasting has limited operating activities since incorporation except for holding the ownership interest in Pukung Limited (“Pukung”), a company organized under the laws of Hong Kong. Pukung owns 100% of the equity interest in Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”), a company organized under the laws of the PRC. Xinrongxin owns all the ownership interest of Dalian Boqi Zhengji Pharmacy Chain Co., Ltd. (“Boqi Zhengji”). Boqi Zhengji operated 16 retail pharmacy stores in China at the time of the acquisition (collectively, the “Boqi Pharmacy Group”). Lasting, Pukung, Xinrongxin and Boqi Zhengji are hereinafter collectively referred to as the “Boqi Zhengji Group”. Xinrongxin also owns 100% equity interests in Dalian Boyi Technology Co., Ltd. (“Dalian Boyi”), a subsidiary established in January 2020 and responsible for the Company’s R&D and other technology related functions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 24, 2020, the Company established a wholly owned subsidiary Boyi (Liaoning) Technology Co. Ltd (“Liaoning Boyi”), in order to be qualified to participate in local healthcare projects. On December 22, 2020, the Company established another subsidiary, Bimai Pharmaceutical (Chongqing) Co., Ltd. (“Chongqing Bimai”), to replace Xinronxin as the holding company for all the retail, wholesale and hospital operations in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On March 18, 2020, the Company, through its wholly owned subsidiary, Xinrongxin, acquired 100% of the equity interests in Chongqing Guanzan Technology Co., Ltd. (“Guanzan”). Guanzan held an 80% equity interest in Chongqing Shude Pharmaceutical Co., Ltd. (“Shude”, collectively with Guanzan, the “Guanzan Group”). Guanzan also owns 100% equity interest in Chongqing Lijiantang Pharmaceutical Co. Ltd., a subsidiary established in May 2020. Lijiantang operates 4 retail pharmacy stores in China (collectively, the “Lijiantang Pharmacy Group”,”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 11, 2020, the Company entered into a stock purchase agreement to sell Boqi Zhengji. The sale of the Boqi Zhengji was closed by the end of 2020, although the government record was not updated until February 2, 2021 due to the Chinese government’s alternative working schedule and other delays caused by COVID-19.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 9, 2020, the Company entered into an agreement to acquire 100% of the equity interests in Chongqing Guoyitang Hospital (“Guoyitang”), the owner and operator of a private general hospital in Chongqing City, a city in Southwest China. The transaction closed on February 2, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 15, 2020, the Company entered into a stock purchase agreement to acquire Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan”), a private hospital in the east region of China. The transaction closed on February 5, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 9, 2021, the Company entered into a stock purchase agreement to acquire three private hospitals in the PRC, Wuzhou Qiangsheng Hospital (“Qiangsheng”), Suzhou Eurasia Hospital(“Eurasia”) and Yunnan Yuxi MinKang hospital (“Minkang”). The transaction closed on May 6, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 21, 2021, Bimai Hospital Management (Chongqing) Co. Ltd. was incorporated in the PRC by the Company to manage the operations of the Company’s medical devices segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 21, 2021, Pusheng Pharmaceutical Co., Ltd. was incorporated in the PRC by the Company to manage its wholesale distribution of generic drugs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On September 10, 2021, the Company entered into a stock purchase agreement to acquire 100% of the equity interests in Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”). The transaction closed on October 8, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">On December 20, 2021, the Company entered into a stock purchase agreement to acquire Bengbu Mali OB-GYN Hospital Co., Ltd. (“Mali Hospital”). We agreed to purchase all the issued and outstanding equity interests in Mali Hospital in consideration of $16,750,000. On January 4, 2022, we paid RMB7,227,000 to the seller as partial consideration. The transaction did not close and on December 15, 2022, the Company entered into a termination agreement with respect to the purchase of Mali Hospital. Pursuant to the termination agreement, the original agreement will terminate effective as of the date of the return of the 60,000 shares of the Company’s common stock previously issued to the sellers of Mali Hospital and certain third-party beneficiaries. Such return is expected to take place promptly. The Company did not incur any penalties as a result of the termination of the Original Agreement. As of the date of this annual report, we have not received the refund of RMB7,227,000 we paid on January 4, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Pharmacy Group engages in the retail sale of medicine and other healthcare products in the PRC. The Pharmacy Group sells its medicine and other healthcare products to customers through its directly-owned stores. The Pharmacy Group offers a wide range of products, including prescription and over-the-counter (“OTC”) drugs, nutritional supplements, traditional Chinese medicines, personal and family care products and medical devices, as well as miscellaneous items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company’s wholesale segments are engaged in the distribution of medical devices and pharmaceuticals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company’s medical services segments are engaged in providing medical services in the hospitals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As of December 31,2022, the details of the Company’s major subsidiaries are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Place of incorporation and<br/> kind of legal entity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal activities and<br/> place of operation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Effective <br/> interest held(%)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 32%; text-align: left">Lasting Wisdom Holdings Limited</td><td style="width: 1%"> </td> <td style="width: 24%; text-align: left">British Virgin Island, a limited liability company</td><td style="width: 1%"> </td> <td style="width: 24%; text-align: left">Investment holding</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">100</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Pukung Limited</td><td> </td> <td style="text-align: left">Hong Kong, a limited liability company</td><td> </td> <td style="text-align: left">Investment holding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Beijing Xinrongxin Industrial Development Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Investment holding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Boyi (Liaoning) Technology Co., Ltd</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">IT Technology service research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Dalian Boyi Technology Co., Ltd</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">IT Technology service research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Chongqing Guanzan Technology Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Wholesale distribution of medical devices in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Chongqing Shude Pharmaceutical Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Chongqing Lijiantang Pharmaceutical Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Bimai Pharmaceutical (Chongqing) Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Investment holding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Chongqing Guoyitang Hospital Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Chongqing Huzhongtang Healthy Technology Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Chaohu Zhongshan Minimally Invasive Hospital Co.,Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Yunnan Yuxi Minkang Hospital Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Wuzhou Qiangsheng Hospital Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Suzhou Eurasia Hospital Co., Ltd.</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Bimai Hospital Management (Chongqing) Co. Ltd</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Hospital management in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Pusheng Pharmaceutical Co., Ltd</td><td> </td> <td style="text-align: left">The PRC, a limited liability company</td><td> </td> <td style="text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> </table>
CY2021Q4	us-gaap	Interest And Fee Income Loans Consumer Home Equity InterestAndFeeIncomeLoansConsumerHomeEquity	16750000	usd
CY2022Q1	us-gaap	Interest And Fee Income Loans Consumer Home Equity InterestAndFeeIncomeLoansConsumerHomeEquity	7227000	cny
CY2022Q1	us-gaap	Customer Refundable Fees CustomerRefundableFees	7227000	cny
CY2022Q4	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	59567	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	22393259	usd
CY2021	us-gaap	Other Operating Income OtherOperatingIncome	34985956	usd
CY2022	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	10255206	usd
CY2021	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	4436774	usd
CY2022Q4	bimi	Net Current Liabilities Percentage NetCurrentLiabilitiesPercentage	21266.72	pure
CY2021Q4	bimi	Net Current Liabilities Percentage NetCurrentLiabilitiesPercentage	9324.92	pure
CY2022Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	70143785	usd
CY2021Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	47900930	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	2252401	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	2091927	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The preparation of the consolidated financial statements in conformity with the U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Significant estimates and assumptions made by management include, among others, useful lives and impairment of long-lived assets, impairment of goodwill, collectability of accounts receivable, advances to suppliers, allowance for doubtful accounts, reserve of inventory and valuation of derivative liabilities. While the Company believes that the estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>
CY2021	bimi	Addition During The Year AdditionDuringTheYear		usd
CY2022	bimi	Accounts Receivables Contractual Term AccountsReceivablesContractualTerm	P90D
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1380929	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	53698	usd
CY2021Q4	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	93884	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5385811	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	26128171	usd
CY2022Q4	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	6.7261	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2022Q4	bimi	Percentage Of Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement PercentageOfIncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement	0.13	pure
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.9646	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.3757	pure
CY2022Q4	bimi	Shares Issued For Interest Payment SharesIssuedForInterestPayment		usd
CY2021Q4	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	6.4515	pure
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	pure
CY2020Q4	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	7374000	usd
CY2022Q4	us-gaap	Other Minority Interests OtherMinorityInterests	46295	usd
CY2022	bimi	Non Controlling Equity Interest Percentage NonControllingEquityInterestPercentage	0.20	pure
CY2021Q2	us-gaap	Investment Company Committed Capital InvestmentCompanyCommittedCapital	4892293	usd
CY2020Q4	bimi	Partial Consideration PartialConsideration	6100723	usd
CY2020Q4	bimi	Partial Consideration PartialConsideration	40000000	cny
CY2021Q1	bimi	Common Stock Shares CommonStockShares	400000	shares
CY2022	bimi	Heacquisitionoftheqiangshengeurasiaandminkanghospitals HEACQUISITIONOFTHEQIANGSHENGEURASIAANDMINKANGHOSPITALS	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE ACQUISITION OF THE QIANGSHENG, EURASIA AND MINKANG HOSPITALS</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 9, 2021, the Company and Chongqing Bimai entered into a stock purchase agreement to acquire three private hospitals in the PRC, the Qiangsheng, Eurasia and Minkang hospitals. Pursuant to the agreement, the Company agreed to purchase all the issued and outstanding equity interests in the three hospitals in consideration of approximately $25,023,555 (RMB162,000,000) to paid by the issuance of 4,000,000 shares of Common Stock, the value of which was agreed to be RMB 78 million or $12 million and the payment of RMB 84,000,000 (approximately $13,008,734) in cash (the “Cash Consideration”). The first payment of the Cash Consideration was RMB 20,000,000 (approximately $3,097,317). The second and third payments of the Cash Consideration of RMB 64,000,000 (approximately $9,911,416) were subject to post-closing adjustments based on the performance of Qiangsheng, Eurasia and Minkang in 2021 and 2022. The sellers had the right to receive the second and third payments in the form of shares of Common Stock valued at $15.00 per share or in cash. The transaction closed on May 6, 2021, at which time 4,000,000 shares of Common Stock were issued. As a result of the performance failure by the three hospitals for the year ended December 31, 2021, the sellers are not eligible to receive any contingent payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following summarizes the identified assets acquired and liabilities assumed pursuant to the Qiangsheng, Eurasia and Minkang acquisitions as of May 6, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; padding-left: 0in; font-weight: bold; text-align: left">Items</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0in; font-weight: bold; text-align: left">Assets</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,341</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Accounts receivable, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,836</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Inventories, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156,576</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Advances and other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,620</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Property, plant and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">653,104</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Operating lease-right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,168,709</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,067,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; font-weight: bold; text-align: left">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accounts payable, trade</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(355,980</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Advances from customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,798</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Tax payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(345,870</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Other payables and accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(311,174</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Lease liability-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(365,788</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Lease liability-non current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,988,195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; font-weight: bold; text-align: left">Total net assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,736,910</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fair value of all assets acquired and liabilities assumed is the estimated book value of the Qiangsheng, Eurasia and Minkang hospitals. Goodwill represents the excess of the fair value of purchase price over the amounts assigned to the fair value of the assets acquired and the liabilities assumed of Qiangsheng, Eurasia and Minkang Hospitals at the acquisition date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.05pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 28, 2022, we entered into an agreement to transfer 90% of the equity interests in Qiangsheng, Minkang and Eurasia to the previous owners. As consideration for the transfer, the sellers agreed to return to us the 80,000 shares of Common Stock which were previously issued upon the acquisition of the three hospitals. The sales of Qiangsheng, Minkang and Eurasia are expected to close in the second quarter of 2023.</p>
CY2021Q2	us-gaap	Stock Issued1 StockIssued1	4000000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12341	usd
CY2021Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	41836	usd
CY2021Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	156576	usd
CY2021Q2	us-gaap	Other Receivables OtherReceivables	40620	usd
CY2021Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment	653104	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2168709	usd
CY2021Q2	us-gaap	Goodwill Goodwill	9067529	usd
CY2021Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	355980	usd
CY2021Q2	bimi	Advances From Customer AdvancesFromCustomer	-36798	usd
CY2021Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	345870	usd
CY2021Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	311174	usd
CY2021Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	365788	usd
CY2021Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	1988195	usd
CY2021Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	8736910	usd
CY2022Q4	bimi	Equity Method Investments Summarized Financial Information Minority Interest EquityMethodInvestmentsSummarizedFinancialInformationMinorityInterest	0.90	pure
CY2022Q4	us-gaap	Stock Issued1 StockIssued1	80000	usd
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	44000	shares
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	4813160	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6170551	usd
CY2022	bimi	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	-1604874	usd
CY2021	bimi	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	-295945	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3208286	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5874607	usd
CY2022	us-gaap	Payments To Suppliers PaymentsToSuppliers	6589759	usd
CY2021	us-gaap	Payments To Suppliers PaymentsToSuppliers	2909048	usd
CY2022	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	6589759	usd
CY2021	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	2909048	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7067613	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	614231	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	302035	usd
CY2022Q4	bimi	Less Impairment Allowance LessImpairmentAllowance	27602	usd
CY2021Q4	bimi	Less Impairment Allowance LessImpairmentAllowance	30152	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7654242	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2238692	usd
CY2022	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	27602	usd
CY2021	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	30152	usd
CY2022Q4	bimi	Rental Security Deposits RentalSecurityDeposits	132960	usd
CY2021Q4	bimi	Rental Security Deposits RentalSecurityDeposits	39180	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	56121	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	73566	usd
CY2022	us-gaap	Increase Decrease In Earnest Money Deposits Outstanding IncreaseDecreaseInEarnestMoneyDepositsOutstanding	166765	usd
CY2021Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	297141	usd
CY2021Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	1227778	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	24337	usd
CY2022Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	66986	usd
CY2021Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	61781	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	923785	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	137816	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	23875	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	26080	usd
CY2022Q4	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	1347079	usd
CY2021Q4	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	1811182	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	23875	usd
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	26080	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2642346	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2833772	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	938926	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	888220	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1703420	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1945552	usd
CY2022	us-gaap	Depreciation Depreciation	220064	usd
CY2021	us-gaap	Depreciation Depreciation	240660	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	19679	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	21495	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19679	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21495	usd
CY2022Q4	bimi	H Less Accumulated Amortization HLessAccumulatedAmortization	-3496	usd
CY2021Q4	bimi	H Less Accumulated Amortization HLessAccumulatedAmortization	-3456	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16183	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18039	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3496	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3456	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1402550	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3107381	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1845178	usd
CY2021Q4	bimi	Shares Issued For Interest Payment SharesIssuedForInterestPayment		usd
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	1800000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1800000	usd
CY2022Q3	bimi	Equity Interests Percentage EquityInterestsPercentage	1	pure
CY2022Q3	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	1800000	usd
CY2022	bimi	Cash Purchase CashPurchase	180000	usd
CY2022	bimi	Total Shares Issued TotalSharesIssued	5270000	shares
CY2022	bimi	Shares Issued One SharesIssuedOne	270000	shares
CY2022	bimi	Balance Shares BalanceShares	5000000	shares
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	2500000	usd
CY2022Q4	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	2942265	usd
CY2021Q4	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	1708740	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2942265	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1708740	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	532630	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	442628	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2574751	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	683240	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	760535	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	773941	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	787224	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	743755	usd
CY2022	bimi	Total Minimum Lease Payments TotalMinimumLeasePayments	3748695	usd
CY2022	bimi	Less Amounts Representing Interest LessAmountsRepresentingInterest	-641314	usd
CY2022Q4	bimi	Operating Lease Total OperatingLeaseTotal	3107381	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	34504388	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	924740	usd
CY2022	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	5385811	usd
CY2021	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	26128171	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	2065666	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
CY2022	us-gaap	Goodwill Transfers GoodwillTransfers	2065666	usd
CY2021	us-gaap	Goodwill Transfers GoodwillTransfers	8376217	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5385811	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	26128171	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	818425	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	768543	usd
CY2022	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	65807	usd
CY2022	us-gaap	Exchange Fees ExchangeFees		usd
CY2021	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	41076	usd
CY2022Q4	us-gaap	Other Loans Payable OtherLoansPayable	420751	usd
CY2021Q4	us-gaap	Other Loans Payable OtherLoansPayable	907193	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	105965	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	369187	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	314786	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	538006	usd
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0945	pure
CY2022Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	119653	usd
CY2022Q3	us-gaap	Long Term Debt Term LongTermDebtTerm	P2Y
CY2022Q3	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.144	pure
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	75962	usd
CY2021	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	106600	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	105965	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	369187	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	475152	usd
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	12.95
CY2022Q4	bimi	Shares Of Common Stock SharesOfCommonStock	130000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.23
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	5400000	usd
CY2021Q1	bimi	Shares Of Common Stock SharesOfCommonStock	152000	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.23
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5211160	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3328447	usd
CY2022Q4	bimi	Interest Accrued At Effective Interest Rate InterestAccruedAtEffectiveInterestRate	2585840	usd
CY2021Q4	bimi	Interest Accrued At Effective Interest Rate InterestAccruedAtEffectiveInterestRate	7282713	usd
CY2022Q4	bimi	Redemption Of Convertible Promissory Note RedemptionOfConvertiblePromissoryNote	-7797000	usd
CY2021Q4	bimi	Redemption Of Convertible Promissory Note RedemptionOfConvertiblePromissoryNote	-5400000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1108785	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5211160	usd
CY2021Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	the “November SPA”) with the same two Institutional Investors to sell them a series of senior convertible notes (the “2021 Notes”) with an original issue discount of 20% and ranking senior to all outstanding and future indebtedness of the Company in a private placement. Each Institutional Investor paid $3,250,000 in cash for a 2021 Note in the face amount of $3,900,000. The November SPA also provided for the issuance of additional 2021 Notes in an aggregate original principal amount not to exceed $3,900,000 under certain circumstances. The November SPA also contains provisions about the Market Event Price. The 2021 Notes, which were issued on November 22, 2021, mature on the eighteen-month anniversary of the issuance date, are payable by the Company in installments and are convertible at the election of the Institutional Investors at the conversion price of $3.25 (post-Split Price and subject to the Event Market Price Adjustment), which is subject to adjustment in the event of default. Each Institutional Investor also received a warrant (the “Institutional Investor 2021 Warrant”) to purchase 180,000 shares of Common Stock at an initial exercise price of $3.55 per share (subject to the Event Market Price Adjustment). The placement agent for the private placement received a warrant (the “Placement Agent 2021 Warrant”, together with the Institutional Investor 2021 Warrant, the “2021 Warrants”) to purchase up to 8% of the aggregate number of shares of Common Stock at an initial exercise price of $3.55 per share (post-Split Price and subject to the Event Market Price Adjustment), subject to increase based on the number of shares Common Stock issued pursuant to the 2021 Notes.
CY2022Q4	bimi	Convertible Note Principal ConvertibleNotePrincipal	1108785	usd
CY2021Q4	bimi	Convertible Note Principal ConvertibleNotePrincipal	7800000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2588840	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	1108785	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	5211160	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y5M1D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y5M1D
CY2022Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	4600441	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	730285	usd
CY2022	us-gaap	Loan Processing Fee LoanProcessingFee	2000000	usd
CY2022Q4	us-gaap	Longterm Construction Loan Current And Noncurrent LongtermConstructionLoanCurrentAndNoncurrent	1620000	usd
CY2022Q4	bimi	Payroll Payable Current PayrollPayableCurrent	411043	usd
CY2021Q4	bimi	Payroll Payable Current PayrollPayableCurrent	671147	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2135333	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1005833	usd
CY2022Q4	bimi	Accrued Operating Expenses AccruedOperatingExpenses	-900	usd
CY2021Q4	bimi	Acquisition Payable AcquisitionPayable	403305	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	630097	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3175574	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2080285	usd
CY2019Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	500000	usd
CY2021Q4	bimi	Employment Agreement Term EmploymentAgreementTerm	P1Y
CY2021	us-gaap	Exchange Fees ExchangeFees		usd
CY2021Q4	us-gaap	Salaries And Wages SalariesAndWages	1000000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	100000	shares
CY2021Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	250000	usd
CY2022	bimi	Employment Agreement Term EmploymentAgreementTerm	P1Y
CY2022	us-gaap	Salaries And Wages SalariesAndWages	500000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	500000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15806052	shares
CY2021Q1	bimi	Aggregate Principal Amounts AggregatePrincipalAmounts	74473	usd
CY2022Q1	us-gaap	Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued	500000	usd
CY2022Q1	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	500000	shares
CY2022Q3	us-gaap	Shares Issued SharesIssued	12500000	shares
CY2022Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	5	usd
CY2022Q4	us-gaap	Shares Issued SharesIssued	44000	shares
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	15806052	shares
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	6276080	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.165	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.25	pure
CY2022	bimi	Income Loss Before Income Taxes IncomeLossBeforeIncomeTaxes	-3479593	usd
CY2021	bimi	Income Loss Before Income Taxes IncomeLossBeforeIncomeTaxes	-1076954	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-869899	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-269239	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1481	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	9057	usd
CY2022	bimi	Income Tax Reconciliation Nonprofitable Expense IncomeTaxReconciliationNonprofitableExpense	874510	usd
CY2021	bimi	Income Tax Reconciliation Nonprofitable Expense IncomeTaxReconciliationNonprofitableExpense	596660	usd
CY2021	bimi	Tax Effect Of Preferential Tax Rate TaxEffectOfPreferentialTaxRate	-306806	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6092	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29674	usd
CY2022	bimi	Effective Vat Rate Percentage EffectiveVatRatePercentage	0.13	pure
CY2022	bimi	Value Added Tax Payable ValueAddedTaxPayable	7893	usd
CY2021	bimi	Value Added Tax Payable ValueAddedTaxPayable	11163	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	642	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-21628406	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-34693619	usd
CY2022	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	-689650	usd
CY2021	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	-228126	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22318056	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-34921745	usd
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2664653	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	536293	shares
CY2022	bimi	Continuing Operations ContinuingOperations	-8.12
CY2021	bimi	Continuing Operations ContinuingOperations	-64.69
CY2022	bimi	Income Loss From Discontinued Operations Basic And Diluted IncomeLossFromDiscontinuedOperationsBasicAndDiluted	-0.26
CY2021	bimi	Income Loss From Discontinued Operations Basic And Diluted IncomeLossFromDiscontinuedOperationsBasicAndDiluted	-0.43
CY2022	bimi	Total Loss Per Share TotalLossPerShare	-8.38
CY2021	bimi	Total Loss Per Share TotalLossPerShare	-65.12
CY2022	bimi	Statutory Reserve StatutoryReserve	0.10	pure
CY2022	bimi	Aftertax Net Income AftertaxNetIncome	0.50	pure
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	pure
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11830379	usd
CY2022	bimi	Cost Of Revenues CostOfRevenues	9880429	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	77939	usd
CY2022	bimi	Profitloss Profitloss	-21628406	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q4	bimi	Total Assets TotalAssets	29853668	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	21319610	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2021	bimi	Cost Of Revenues CostOfRevenues	18893667	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	170532	usd
CY2021	bimi	Profitloss Profitloss	-34693619	usd
CY2021Q4	bimi	Total Assets TotalAssets	29699202	usd
CY2022	bimi	Total Revenues From Reportable Segments TotalRevenuesFromReportableSegments	12813333	usd
CY2022	bimi	Elimination Of Intersegments Revenues EliminationOfIntersegmentsRevenues	-982954	usd
CY2022	bimi	Total Consolidated Revenues TotalConsolidatedRevenues	11830379	usd
CY2022	bimi	Total Loss From Reportable Segments TotalLossFromReportableSegments	-2727636	usd
CY2022	bimi	Elimination Of Intersegments Profit Or Loss EliminationOfIntersegmentsProfitOrLoss	-696567	usd
CY2022	bimi	Amortization Of Discount Of Notes And Convertible Notes AmortizationOfDiscountOfNotesAndConvertibleNotes	-3260788	usd
CY2022	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	14943415	usd
CY2022	bimi	Total Net Loss TotalNetLoss	-21628406	usd
CY2022Q4	bimi	Total Assets From Reportable Segments TotalAssetsFromReportableSegments	36787755	usd
CY2022Q4	bimi	Elimination Of Intersegments Receivables EliminationOfIntersegmentsReceivables	-15662215	usd
CY2022Q4	bimi	Other Unallocated Assets Phenix Bio Inc OtherUnallocatedAssetsPhenixBioInc	1800000	usd
CY2022Q4	bimi	Other Unallocated Assets Xinrongxin OtherUnallocatedAssetsXinrongxin	4167	usd
CY2022Q4	bimi	Other Unallocated Assets Liaoning Boyi OtherUnallocatedAssetsLiaoningBoyi	30654	usd
CY2022Q4	bimi	Other Unallocated Assets Dalian Boyi OtherUnallocatedAssetsDalianBoyi	3975	usd
CY2022Q4	bimi	Other Unallocated Assets Chongqing Bimai OtherUnallocatedAssetsChongqingBimai	1624154	usd
CY2022Q4	bimi	Other Unallocated Assets Bimi OtherUnallocatedAssetsBIMI	5265178	usd
CY2022Q4	bimi	Total Consolidated Assets TotalConsolidatedAssets	29853668	usd
CY2021	bimi	Total Revenues From Reportable Segments TotalRevenuesFromReportableSegments	25685842	usd
CY2021	bimi	Other Revenues OtherRevenues	14165	usd
CY2021	bimi	Elimination Of Intersegments Revenues EliminationOfIntersegmentsRevenues	-4380397	usd
CY2021	bimi	Total Consolidated Revenues TotalConsolidatedRevenues	21319610	usd
CY2021	bimi	Total Loss From Reportable Segments TotalLossFromReportableSegments	482368	usd
CY2021	bimi	Elimination Of Intersegments Profit Or Loss EliminationOfIntersegmentsProfitOrLoss	-671410	usd
CY2021	bimi	Amortization Of Discount Of Notes And Convertible Notes AmortizationOfDiscountOfNotesAndConvertibleNotes	-2252401	usd
CY2021	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	15201469	usd
CY2021	bimi	Total Net Loss TotalNetLoss	-17642912	usd
CY2021Q4	bimi	Total Assets From Reportable Segments TotalAssetsFromReportableSegments	36523225	usd
CY2021Q4	bimi	Elimination Of Intersegments Receivables EliminationOfIntersegmentsReceivables	-25344121	usd
CY2021Q4	bimi	Other Unallocated Assets Dalian Boyi OtherUnallocatedAssetsDalianBoyi	21955	usd
CY2021Q4	bimi	Other Unallocated Assets Chongqing Bimai OtherUnallocatedAssetsChongqingBimai	18173386	usd
CY2021Q4	bimi	Other Unallocated Assets Liaoning Boyi OtherUnallocatedAssetsLiaoningBoyi	33847	usd
CY2021Q4	bimi	Other Unallocated Assets Xinrongxin OtherUnallocatedAssetsXinrongxin	3188516	usd
CY2021Q4	bimi	Other Unallocated Assets Bimi OtherUnallocatedAssetsBIMI	5531557	usd
CY2021Q4	bimi	Total Consolidated Assets TotalConsolidatedAssets	38128365	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	bimi	Schedule Of Revenues From Each Types Of Products Table Txet Block ScheduleOfRevenuesFromEachTypesOfProductsTableTxetBlock	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended<br/> December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Medical devices wholesale</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,142,455</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,445,107</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Pharmaceuticals wholesale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,831,328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,495,373</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Medical services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,048,318</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Pharmacy retail</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">856,596</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">316,647</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,165</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,830,379</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,319,610</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: left"> </p>
CY2022	bimi	Total Revenue TotalRevenue	11830379	usd
CY2021	bimi	Total Revenue TotalRevenue	21319610	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2021	bimi	Accounts Receivable Percentage AccountsReceivablePercentage	0.10	pure
CY2022Q4	us-gaap	Investment Sold Not Yet Purchased Percent Of Net Assets InvestmentSoldNotYetPurchasedPercentOfNetAssets	0.10	pure
CY2022Q4	us-gaap	Shares Issued SharesIssued	200000	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	400000	shares
CY2022Q3	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	180000	usd
CY2022Q3	us-gaap	Shares Issued SharesIssued	5270000	shares
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	270000	shares
CY2022Q3	bimi	Aggregate Net Profit AggregateNetProfit	2500000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2000000	usd
CY2022Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.06	pure
CY2022Q4	bimi	Conversion Price ConversionPrice	0.4
CY2022Q4	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.60	pure
CY2022Q4	us-gaap	Share Price SharePrice	0.25
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent		usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments		usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent		usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3764780	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3764780	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	850222	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	850222	shares
CY2021Q4	bimi	Accrued Operating Expenses AccruedOperatingExpenses		usd
CY2022Q4	bimi	Social Security Payable SocialSecurityPayable		usd
CY2021Q4	bimi	Social Security Payable SocialSecurityPayable		usd
CY2022	bimi	Common Stock To Be Issued Upon Conversion Of Convertible Promissory Notes CommonStockToBeIssuedUponConversionOfConvertiblePromissoryNotes		usd
CY2021	bimi	Common Stock To Be Issued Upon Conversion Of Convertible Promissory Notes CommonStockToBeIssuedUponConversionOfConvertiblePromissoryNotes		usd
CY2022Q4	bimi	Acquisition Payable AcquisitionPayable		usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent		usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2022	bimi	Tax Effect Of Preferential Tax Rate TaxEffectOfPreferentialTaxRate		usd
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2664653	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	536293	shares
CY2022	bimi	Other Revenues OtherRevenues		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001213660
CY2022Q2	dei	Entity Public Float EntityPublicFloat	0	usd

Files In Submission

Name	View Source	Status
bimi-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_bimiinter_htm.xml	Edgar Link	completed
0001213900-23-036407-index-headers.html	Edgar Link	pending
0001213900-23-036407-index.html	Edgar Link	pending
0001213900-23-036407.txt	Edgar Link	pending
0001213900-23-036407-xbrl.zip	Edgar Link	pending
bimi-20221231.xsd	Edgar Link	pending
ex3-10_001.jpg	Edgar Link	pending
ex3-10_002.jpg	Edgar Link	pending
ex3-6_001.jpg	Edgar Link	pending
ex3-6_002.jpg	Edgar Link	pending
ex3-8_001.jpg	Edgar Link	pending
ex3-8_002.jpg	Edgar Link	pending
f10k2022ex21-1_bimiinter.htm	Edgar Link	pending
f10k2022ex23-1_bimiinter.htm	Edgar Link	pending
f10k2022ex3-10_bimiinter.htm	Edgar Link	pending
f10k2022ex3-6_bimiinter.htm	Edgar Link	pending
f10k2022ex3-8_bimiinter.htm	Edgar Link	pending
f10k2022ex31-1_bimiinter.htm	Edgar Link	pending
f10k2022ex31-2_bimiinter.htm	Edgar Link	pending
f10k2022ex32-1_bimiinter.htm	Edgar Link	pending
f10k2022ex32-2_bimiinter.htm	Edgar Link	pending
f10k2022_bimiinter.htm	Edgar Link	pending
bimi-20221231_def.xml	Edgar Link	unprocessable
bimi-20221231_lab.xml	Edgar Link	unprocessable
bimi-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIMI
BIMI Holdings Inc. Stock $bimi

2023 Q2 Form 10-K Financial Statement

#000121390023036407 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI BIMI Holdings Inc. Stock $bimi

2023 Q2 Form 10-K Financial Statement

#000121390023036407 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI
BIMI Holdings Inc. Stock $bimi